Oragenics, Inc. (OGEN) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Oragenics, Inc. is a development-stage biopharmaceutical company focused on nasally delivered therapies for neurological conditions. Its primary asset is ONP-002, a novel formulation for the treatment of mild traumatic brain injury (concussion). The company is currently advancing ONP-002 toward Phase 2a clinical trials. On June 3, 2025, the company effected a 1-for-30 reverse stock split, and all share data in this report reflects that adjustment.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3.07) million | $(2.46) million | $(7.56) million | $(7.22) million |
| Operating Expenses | $3.12 million | $2.44 million | $6.86 million | $7.20 million |
| Cash and Equivalents (End of Period) | $11.40 million (Sep 30, 2025) vs $0.86 million (Dec 31, 2024) |
|||
| Accumulated Deficit | ||||
| Short-Term Debt | $0.39 million (Sep 30, 2025) | |||
| Stockholders' Equity | $9.83 million (Sep 30, 2025) |
Material Changes vs. Prior Period
- Liquidity Transformation: Cash balances surged from $0.86 million at year-end 2024 to $11.40 million at September 30, 2025. This was driven by a July 2025 public offering of Series H Preferred Stock and warrants, which generated approximately $15.2 million in net proceeds.
- Debt Repayment: The company repaid a $3.0 million promissory note issued in March 2025 in full during July 2025 using proceeds from the Series H offering. Remaining short-term debt consists of insurance premium financing.
- Expense Fluctuations:
- Q3 2025: Operating expenses increased 28% year-over-year to $3.12 million, primarily due to a $700,000 accrual for a legal settlement with Ladenburg Thalmann & Co. and higher professional fees.
- YTD 2025: Operating expenses decreased 4.7% year-over-year to $6.86 million, reflecting reduced R&D spend on discontinued programs and lower headcount, partially offset by the legal settlement accrual.
- Capital Structure: The company issued 660,000 shares of Series H Preferred Stock (convertible at $2.50/share) and associated warrants. Additionally, 260,000 shares of common stock were sold via an At-The-Market (ATM) agreement in February 2025.
Outlook, Risks, and Management Commentary
- Going Concern: While the July 2025 financing extends the company's runway, management states that substantial doubt about the ability to continue as a going concern remains unless additional capital is secured. Current cash is expected to fund operations through the first half of 2026.
- Development Timeline: The company estimates starting Phase 2a trials in Q4 2025, Phase 2b in Q4 2026, and Phase 3 in Q4 2027. These timelines are contingent on funding and regulatory approvals.
- Legal Settlement: A dispute with Ladenburg Thalmann regarding a fee for the Odyssey Health asset purchase was settled for $700,000, paid in October 2025. This amount was accrued in Q3 2025.
- NYSE Compliance: As of October 20, 2025, the company regained compliance with NYSE American stockholder equity requirements, removing the non-compliance indicator.
- Dilution Risk: The Series H Preferred Stock contains anti-dilution provisions that could lower the conversion price in future offerings, potentially resulting in significant dilution to common shareholders.
Investor Verification Checklist
- Cash Runway: Verify if the $11.4 million cash balance is sufficient to reach the estimated Q4 2025 Phase 2a trial start without further dilution.
- Series H Terms: Review the anti-dilution provisions of the Series H Preferred Stock to understand potential future conversion ratios and dilution impact.
- Legal Resolution: Confirm the full payment of the $700,000 Ladenburg Thalmann settlement and ensure no further claims exist.
- Reverse Split Impact: Ensure all historical share data is correctly adjusted for the 1-for-30 reverse stock split effected in June 2025.
- Capital Needs: Assess the likelihood and terms of future financing required to fund Phase 2b and Phase 3 trials, given the "substantial doubt" going concern qualification.